It's hard to call the current state of the med-tech world healthy, but some companies are definitely starting to do better. Prominent among them is Stryker (NYSE:SYK), which seems to be past its problems in joint reconstruction and back to building for the future. While I have hopes for the company's ongoing cost reduction initiatives and its plans for further M&A, I wouldn't ignore the challenges facing the U.S. orthopedics market. On balance, absent a new major growth driver, I think Stryker is more or less fairly valued today, albeit still a high-quality option in the healthcare space.
Please read the full article here:
http://www.investopedia.com/stock-analysis/071913/stryker-seems-back-track-syk-jnj-cov.aspx
Investopedia: Stryker Seems Back On Track
0 comments:
Post a Comment